期刊
INFLUENZA AND OTHER RESPIRATORY VIRUSES
卷 2, 期 6, 页码 211-219出版社
WILEY
DOI: 10.1111/j.1750-2659.2008.00053.x
关键词
Baculovirus; cell culture; hemagglutinin; influenza; safety; vaccine
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据